YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases
A Phase I Clinical Trial of YMN-A02 in Patients With Advanced pMMR Colorectal Cancer and Liver Metastases: Safety, Tolerability, and Preliminary Efficacy
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 1
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Peng Xingchen Peng
- Telefonní číslo: 86-17723609529
- E-mail: pxx2014@163.com
Studijní místa
-
-
Sichuan
-
Chengdu, Sichuan, Čína, 610041
- West China Hospital
-
Kontakt:
- Peng Xingchen Professor
- Telefonní číslo: 86-18980606753
- E-mail: pxx2014@scu.edu.cn
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Signed the informed consent form approved by the ethics committee.
- 18-70 years old; ECOG performance status 0-1.
- Histologically or cytologically confirmed colorectal cancer with liver metastases, molecularly classified as pMMR (presence of other distant metastases allowed).
Patients who have failed or are intolerant to standard therapy, or who refuse standard therapy.
- For patients with RAS/BRAF wild-type and eligible for targeted therapy: enrollment allowed only after disease progression on a prior standard regimen containing anti-EGFR or anti-VEGF monoclonal antibody.
- For patients with BRAF V600E mutation: enrollment allowed only after failure of a prior BRAF inhibitor-containing chemotherapy regimen.
- For patients who do not meet the above molecular characteristics: enrollment allowed only after failure of at least two prior lines of systemic chemotherapy (including a platinum-containing regimen).
- At least one measurable liver metastasis (CT scan long diameter ≥10 mm, slice thickness ≤5 mm).
- Life Expectancy≥3 months.
Adequate Major Organ Function (all within 14 days before randomization):
- Hemoglobin ≥80 g/L (no transfusion within 14 days); absolute neutrophil count >1.5×10⁹/L; platelet count ≥80×10⁹/L.
- Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN (or ≤5×ULN in the presence of liver metastases); creatinine clearance ≥60 mL/min (Cockcroft-Gault formula).
- Left ventricular ejection fraction (LVEF) ≥50%.
- Good compliance, and family agrees to cooperate with survival follow-up.
Exclusion Criteria:
- Participation in another interventional drug trial within 4 weeks before enrollment.
- Prior or concurrent other malignancy, except: carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, superficial bladder tumor, or any other malignancy that has been curatively treated and recurrence-free for ≥5 years.
- Poorly controlled heart disease or clinical symptoms, including but not limited to: NYHA class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
- Pregnant or breastfeeding women.
- Active infection, including but not limited to: active tuberculosis, systemic bacterial or fungal infection (NCI-CTCAE v5.0 grade ≥2), HIV infection, active HBV (HBV DNA >ULN), or active HCV (HCV RNA >ULN).
- History of substance abuse that cannot be abstained from, or history of psychiatric disorders.
- Active or history of autoimmune disease (including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism, etc.). Exceptions: vitiligo controlled with only topical agents; childhood asthma completely resolved without any intervention in adulthood. Patients with asthma requiring bronchodilators for medical intervention are excluded.
- Prior vaccination with any mRNA-based drug or mRNA formulation.
- Prior participation in any clinical trial involving lipid nanoparticle (LNP) formulations.
- Contraindications to intravenous infusion.
- History of drug abuse, or any medical, psychological, or social condition (e.g., alcoholism or drug addiction) that, in the investigator's judgment, may affect study compliance.
- Known allergy, hypersensitivity, or intolerance to any component (active substance or excipients) of the study drug; history of severe allergy to drugs, food, or vaccines, including but not limited to anaphylactic shock, angioedema of the larynx, anaphylactic dyspnea, allergic purpura, thrombocytopenic purpura, or Arthus reaction.
- Plan to conceive (either female subject or partner of male subject) from screening through 12 months after the last dose.
- Any concurrent condition that, in the investigator's judgment, may compromise patient safety or interfere with study completion.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: YMN-A02 100 μg Group
Enrolled subjects will receive a 100 μg intravenous infusion.
|
Enrolled subjects will receive a 100 μg intravenous infusion according to their assigned dose group.
The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment.
The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose.
The DLT observation period is from the first infusion to 14 days after the third infusion.
Ostatní jména:
|
|
Experimentální: YMN-A02 250 μg Group
Enrolled subjects will receive a 250 μg intravenous infusion.
|
Enrolled subjects will receive a 250 μg intravenous infusion according to their assigned dose group.
The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment.
The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose.
The DLT observation period is from the first infusion to 14 days after the third infusion.
|
|
Experimentální: YMN-A02 500 μg Group
Enrolled subjects will receive a 500 μg intravenous infusion.
|
Enrolled subjects will receive a 500 μg intravenous infusion according to their assigned dose group.
The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment.
The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose.
The DLT observation period is from the first infusion to 14 days after the third infusion.
|
|
Experimentální: YMN-A02 1000 μg Group
Enrolled subjects will receive a 1000 μg intravenous infusion.
|
Enrolled subjects will receive a 1000 μg intravenous infusion according to their assigned dose group.
The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment.
The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose.
The DLT observation period is from the first infusion to 14 days after the third infusion.
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Occurrence of Dose-Limiting Toxicity (DLT)
Časové okno: From first dose to 14 days after the third dose, approximately Day 0 to Day 42
|
Observe and record the occurrence of DLTs.
DLT is defined as treatment-related adverse events or clinically significant laboratory abnormalities occurring during the DLT observation period, graded according to NCI CTCAE v5.0.
|
From first dose to 14 days after the third dose, approximately Day 0 to Day 42
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-Free Survival (PFS)
Časové okno: Within 2 years after the first dose
|
Assess disease progression per RECIST v1.1, calculating the time from start of treatment to first documented disease progression or death from any cause.
|
Within 2 years after the first dose
|
|
Objective Response Rate (ORR)
Časové okno: Within 6 months after the first dose
|
Tumor response assessed per RECIST v1.1 for solid tumors.
ORR is the proportion of patients whose tumor volume reduction reaches a predefined value and is maintained for a minimum required duration, calculated as the sum of complete response (CR) and partial response (PR) rates.
|
Within 6 months after the first dose
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Changes in Peripheral Blood Lymphocyte Subsets
Časové okno: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Peripheral blood lymphocytes will be isolated from whole blood using lymphocyte separation medium.
Flow cytometry will be used to detect T cells, B cells, macrophages, NK cells, and regulatory T cells (Tregs).
|
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
|
Percentage of Dendritic Cells Expressing Maturation/Activation Markers
Časové okno: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Dendritic cells (DCs) will be isolated from peripheral blood and labeled with antibodies against surface markers CD80, CD86, and MHC class II molecules.
Flow cytometry will be performed to determine the percentage of DCs positive for each marker.
Maturation and activation status are assessed based on these percentages
|
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
|
Tumor-Infiltrating CD8+ T Cells
Časové okno: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Tumor tissue sections will be stained to identify CD8+ T cells, including stem-like and exhausted CD8+ T cell subsets.
Confocal microscopy and flow cytometry (using single-cell suspensions from tumor tissue) will be used to observe the infiltration status of these cells.
|
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
|
Cytokine Levels Associated with Delayed-Type Hypersensitivity (DTH)
Časové okno: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Plasma will be collected 24-72 hours after administration.
ELISA kits will be used to measure the levels of cytokines including IL-12, IFN-γ, IL-2, and IL-10 to assess the cellular immune response and the impact of the product on immune function.
|
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
Další identifikační čísla studie
- 2026(890)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .